Recently, the AI ​​biotechnology company Yingsi Intelligence applied for listing in Hong Kong. Once the IPO is successful, the company will become the first domestic AI pharmaceutical company. With the generative AI platform Pharma.AI, Insilicon Intelligence can provide end-to-end efficient solutions in the pipeline development process, and rapidly advance the fully self-generated AIDD (AI Drug Discovery and Development) pipeline mainly composed of new drug candidates. Currently, using Pharma.AI, the company has established a diverse and fully internally generated pipeline of 31 projects covering 29 drug targets. Among them, there is one clinical stage asset of phase II study and two clinical stage assets of phase I study. Since the drug…